Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Clinical trial NCT05913661 · UNKNOWN

Trial details

NCT number: NCT05913661
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma Intrahepatic Cholangiocarcinoma Digestive System Neoplasms PD-1 Inhibitor First-line Treatment

Start date: 2023-07-01
Primary completion: 2024-11-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.